Hiroshi Nokihara

10.4k total citations · 2 hit papers
237 papers, 5.9k citations indexed

About

Hiroshi Nokihara is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Hiroshi Nokihara has authored 237 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 177 papers in Oncology, 141 papers in Pulmonary and Respiratory Medicine and 58 papers in Molecular Biology. Recurrent topics in Hiroshi Nokihara's work include Lung Cancer Treatments and Mutations (118 papers), Lung Cancer Research Studies (64 papers) and Lung Cancer Diagnosis and Treatment (46 papers). Hiroshi Nokihara is often cited by papers focused on Lung Cancer Treatments and Mutations (118 papers), Lung Cancer Research Studies (64 papers) and Lung Cancer Diagnosis and Treatment (46 papers). Hiroshi Nokihara collaborates with scholars based in Japan, United States and United Kingdom. Hiroshi Nokihara's co-authors include Noboru Yamamoto, Tomohide Tamura, Yuichiro Ohe, Ikuo Sekine, Hideo Kunitoh, Koji Tsuta, Yutaka Fujiwara, Hidehito Horinouchi, Seiichiro Yamamoto and Toshimi Takano and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Cancer Research.

In The Last Decade

Hiroshi Nokihara

230 papers receiving 5.8k citations

Hit Papers

Epidermal Growth Factor Receptor Gene Mutations and Incre... 2005 2026 2012 2019 2005 2017 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer
    2005 606 citations Yuichiro Ohe, Koji Tsuta et al. profile →
  2. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial
    2017 308 citations Hiroshi Nokihara, Makoto Nishio et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hiroshi Nokihara Japan 40 3.9k 3.3k 1.7k 935 656 237 5.9k
Makoto Maemondo Japan 37 4.3k 1.1× 4.5k 1.4× 1.8k 1.1× 886 0.9× 458 0.7× 181 6.4k
Petr Zatloukal Czechia 33 3.7k 1.0× 3.4k 1.0× 1.6k 0.9× 603 0.6× 410 0.6× 87 5.7k
Alan B. Sandler United States 44 4.5k 1.2× 3.7k 1.1× 2.4k 1.5× 1.0k 1.1× 554 0.8× 109 7.5k
Kiyotaka Yoh Japan 35 3.0k 0.8× 2.6k 0.8× 1.4k 0.8× 740 0.8× 562 0.9× 271 4.6k
Philip Bonomi United States 42 4.9k 1.3× 4.4k 1.3× 2.1k 1.3× 978 1.0× 652 1.0× 241 8.0k
Shunichi Sugawara Japan 36 4.2k 1.1× 3.5k 1.0× 1.1k 0.6× 548 0.6× 507 0.8× 209 5.4k
Martin Sebastian Germany 27 4.1k 1.1× 3.3k 1.0× 1.7k 1.0× 930 1.0× 453 0.7× 117 5.8k
Wendy A. Cooper Australia 35 2.5k 0.7× 2.9k 0.9× 2.0k 1.2× 1.4k 1.4× 313 0.5× 131 5.7k
Noemı́ Reguart Spain 41 2.9k 0.7× 2.6k 0.8× 2.5k 1.5× 875 0.9× 389 0.6× 175 5.5k
M. Catherine Pietanza United States 44 6.0k 1.6× 3.9k 1.2× 1.6k 1.0× 724 0.8× 1.9k 2.8× 121 7.5k

Countries citing papers authored by Hiroshi Nokihara

Since Specialization
Citations

This map shows the geographic impact of Hiroshi Nokihara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshi Nokihara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshi Nokihara more than expected).

Fields of papers citing papers by Hiroshi Nokihara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroshi Nokihara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshi Nokihara. The network helps show where Hiroshi Nokihara may publish in the future.

Co-authorship network of co-authors of Hiroshi Nokihara

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroshi Nokihara. A scholar is included among the top collaborators of Hiroshi Nokihara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroshi Nokihara. Hiroshi Nokihara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Suzuki, Manabu, Masakazu Sugino, Eriko Morino, et al.. (2024). Preliminary investigation of the significance of cavitary lesions in recurrent hemoptysis following bronchial artery embolization for nontuberculous mycobacterial pulmonary disease. Respiratory Investigation. 62(6). 1227–1232. 1 indexed citations
2.
3.
Hanibuchi, Masaki, Eiji Takeuchi, Takashi Haku, et al.. (2023). A multicenter, open‐label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non‐small cell lung cancer. Thoracic Cancer. 14(32). 3232–3239. 2 indexed citations
4.
Mitsuhashi, Atsushi, Kazuya Koyama, Hirokazu Ogino, et al.. (2023). Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade. Cell Reports. 42(3). 112162–112162. 12 indexed citations
5.
Mitsuhashi, Atsushi, Hirokazu Ogino, Hiroshi Nokihara, et al.. (2023). Antipodoplanin antibody enhances the antitumor effects of CTLA‐4 blockade against malignant mesothelioma by natural killer cells. Cancer Science. 115(2). 357–368. 3 indexed citations
6.
Takeuchi, Eiji, Kensuke Kondo, Yoshio Okano, et al.. (2023). Pretreatment eosinophil counts as a predictive biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors. Thoracic Cancer. 14(30). 3042–3050. 17 indexed citations
7.
Toyozawa, Ryo, Kota Itahashi, Yutaka Fujiwara, et al.. (2021). 1292P Two single-arm, multicenter phase-II trials of PD-1 inhibitors in patients with pulmonary sarcomatoid carcinoma (NCCH1603/NCCH1703). Annals of Oncology. 32. S1002–S1003. 4 indexed citations
8.
Okuma, Yusuke, Yasushi Goto, Fumiyoshi Ohyanagi, et al.. (2020). Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma. Cancer Medicine. 9(20). 7418–7427. 14 indexed citations
9.
Kanda, Shintaro, Yuichiro Ohe, Yasushi Goto, et al.. (2020). Five‐year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non‐small‐cell lung cancer. Cancer Science. 111(6). 1933–1942. 12 indexed citations
10.
Tanaka, Midori, Hidehito Horinouchi, Yasushi Goto, et al.. (2018). Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies. ESMO Open. 3(4). e000342–e000342. 10 indexed citations
11.
Horinouchi, Hidehito, Kaoru Kubota, Akihiko Miyanaga, et al.. (2018). Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial. ESMO Open. 3(1). e000288–e000288. 11 indexed citations
12.
Nokihara, Hiroshi, Makoto Nishio, Noboru Yamamoto, et al.. (2018). Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 20(3). e317–e328. 29 indexed citations
13.
Nakamichi, Shinji, Hidehito Horinouchi, Tetsuhiko Asao, et al.. (2017). Comparison of Radiotherapy and Chemoradiotherapy for Locoregional Recurrence of Non–small-cell Lung Cancer Developing After Surgery. Clinical Lung Cancer. 18(6). e441–e448. 19 indexed citations
14.
Okuma, Hitomi Sumiyoshi, Hidehito Horinouchi, Shinsuke Kitahara, et al.. (2016). Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer. Clinical Lung Cancer. 18(2). 234–240.e2. 7 indexed citations
15.
Katsuya, Yuki, Hidehito Horinouchi, Tetsuhiko Asao, et al.. (2016). Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy. Lung Cancer. 99. 4–10. 76 indexed citations
16.
Horinouchi, Hidehito, Yasushi Goto, Shintaro Kanda, et al.. (2015). Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity. International Journal of Radiation Oncology*Biology*Physics. 94(1). 155–162. 6 indexed citations
17.
Kanda, Shintaro, Hidehito Horinouchi, Yutaka Fujiwara, et al.. (2015). Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Lung Cancer. 89(3). 287–293. 27 indexed citations
18.
Saito, Motonobu, Kouya Shiraishi, Kenji Matsumoto, et al.. (2014). A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma. Clinical Cancer Research. 20(18). 4784–4793. 31 indexed citations
19.
Asahina, Hajime, Hiroshi Nokihara, Noboru Yamamoto, et al.. (2012). Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study. Investigational New Drugs. 31(3). 677–684. 33 indexed citations
20.
Yamada, Kazuhiko, Noboru Yamamoto, Yasuhide Yamada, et al.. (2011). Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 17(8). 2528–2537. 140 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Makoto Maemondo Breakdown of academic impact, for papers by Petr Zatloukal Breakdown of academic impact, for papers by Alan B. Sandler Breakdown of academic impact, for papers by Kiyotaka Yoh Breakdown of academic impact, for papers by Philip Bonomi Breakdown of academic impact, for papers by Shunichi Sugawara Breakdown of academic impact, for papers by Martin Sebastian Breakdown of academic impact, for papers by Wendy A. Cooper Breakdown of academic impact, for papers by Noemı́ Reguart Breakdown of academic impact, for papers by M. Catherine Pietanza
Rankless by CCL
2026